WGS

+ Watchlist + Portfolio

GeneDx Holdings Corp.

Regulated industry Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $73.09
52-Week Range: $32.21 – $170.87
Market Cap: $2.29B
P/E (TTM): —
EPS (TTM): -3.63
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 9.38
PEG Ratio: —
Return on Equity: -40.80%
Return on Assets: -7.89%
Gross Margin: 69.38%
Operating Margin: -15.21%
Profit Margin: -23.41%
Current Ratio: 3.30
Debt/Equity: 0.69
Total Debt: $167.40M
Free Cash Flow: $-47.50M
Revenue Growth: 11.40%
Earnings Growth: —
Enterprise Value: $2.21B

WGS Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$234.69M	$202.57M	$305.45M	$427.54M
Cost of Revenue	$261.44M	$112.56M	$111.05M	$129.37M
Gross Profit	-$26.75M	$90.01M	$194.40M	$298.17M
Research & Development	$86.20M	$58.27M	$45.72M	$72.03M
Selling, General & Admin	$338.24M	$199.98M	$171.89M	$239.22M
Operating Expenses	$430.76M	$260.20M	$217.61M	$311.25M
Operating Income	-$457.51M	-$170.19M	-$23.21M	-$13.08M
EBITDA	-$398.20M	-$136.46M	-$1.26M	$12.15M
Pretax Income	-$598.03M	-$176.69M	-$52.63M	-$21.14M
Income Tax	-$49.05M	-$926.00K	-$343.00K	-$116.00K
Net Income	-$548.98M	-$175.77M	-$52.29M	-$21.02M
Diluted EPS	-53.79	-7.23	-1.94	-0.73
Diluted Shares	10.24M	24.31M	26.89M	28.64M

WGS Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$123.93M	$99.68M	$85.21M	$105.00M
Receivables	$43.34M	$32.82M	$37.63M	$74.37M
Inventory	$13.66M	$8.78M	$10.65M	$13.95M
Current Assets	$212.62M	$182.34M	$197.97M	$268.29M
Total Assets	$490.94M	$418.76M	$419.38M	$523.71M
Current Liabilities	$144.30M	$58.82M	$54.82M	$108.91M
Long-Term Debt	$6.25M	$52.69M	$51.91M	$48.18M
Total Debt	$77.13M	$119.27M	$117.38M	$113.17M
Total Liabilities	$237.24M	$190.74M	$174.13M	$215.53M
Retained Earnings	-$1.12B	-$1.30B	-$1.35B	-$1.37B
Shareholders' Equity	$253.71M	$228.02M	$245.25M	$308.18M
Working Capital	$68.33M	$123.52M	$143.15M	$159.38M

WGS Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$319.15M	-$180.15M	-$28.50M	$33.28M
Capital Expenditure	-$14.32M	-$5.71M	-$5.49M	-$19.02M
Free Cash Flow	-$333.48M	-$185.86M	-$33.99M	$14.26M
Depreciation & Amortisation	$59.31M	$33.73M	$21.95M	$25.22M
Stock-Based Compensation	$41.98M	-$326.00K	$9.14M	$32.16M
Investing Cash Flow	-$141.33M	-$43.73M	-$30.13M	-$61.52M
Financing Cash Flow	$197.31M	$186.24M	$44.16M	$48.02M
Net Change in Cash	-$263.17M	-$37.63M	-$14.47M	$19.79M

WGS Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$87.11M	$102.69M	$116.74M	$120.99M	$102.25M	$114.44M
Cost of Revenue	$28.64M	$31.79M	$32.22M	$36.72M	$34.04M	$36.20M
Gross Profit	$58.48M	$70.90M	$84.53M	$84.27M	$68.21M	$78.24M
Research & Development	$12.58M	$15.08M	$19.83M	$24.54M	$19.80M	$19.66M
Selling, General & Admin	$50.45M	$46.10M	$67.19M	$76.13M	$74.59M	$72.73M
Operating Expenses	$63.03M	$61.87M	$87.78M	$98.50M	$94.39M	$93.48M
Operating Income	-$4.55M	$9.03M	-$3.25M	-$14.23M	-$26.18M	-$15.24M
EBITDA	$236.00K	$17.57M	$3.22M	-$7.35M	-$54.89M	-$10.36M
Pretax Income	-$6.08M	$10.56M	-$7.39M	-$18.23M	-$62.42M	-$18.26M
Income Tax	$447.00K	-$246.00K	$247.00K	-$564.00K	$897.00K	-$518.00K
Net Income	-$6.53M	$10.81M	-$7.63M	-$17.67M	-$63.32M	-$17.74M
Diluted EPS	-0.23	0.36	-0.27	—	-2.16	-0.60
Diluted Shares	28.15M	29.75M	28.80M	—	29.34M	29.71M

WGS Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$99.70M	$74.12M	$95.97M	$105.00M	$93.92M	$60.32M
Receivables	$46.06M	$48.03M	$60.94M	$74.37M	$76.93M	$83.61M
Inventory	$12.66M	$11.93M	$10.57M	$13.95M	$12.24M	$17.82M
Current Assets	$225.82M	$204.84M	$237.58M	$268.29M	$270.63M	$246.36M
Total Assets	$446.43M	$463.86M	$493.90M	$523.71M	$506.30M	$481.49M
Current Liabilities	$69.54M	$71.41M	$87.62M	$108.91M	$87.64M	$74.63M
Long-Term Debt	$51.79M	$51.68M	$51.58M	$48.18M	$96.73M	$96.84M
Total Debt	$114.84M	$114.39M	$113.16M	$113.17M	$168.19M	$167.40M
Total Liabilities	$189.03M	$186.73M	$201.64M	$215.53M	$252.18M	$237.26M
Retained Earnings	-$1.36B	-$1.35B	-$1.36B	-$1.37B	-$1.44B	-$1.45B
Shareholders' Equity	$257.40M	$277.13M	$292.26M	$308.18M	$254.12M	$244.22M
Working Capital	$156.28M	$133.43M	$149.96M	$159.38M	$182.99M	$171.73M
Net Debt	—	—	—	—	$2.81M	$36.52M

WGS Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	$10.18M	$10.42M	$15.77M	-$3.09M	-$32.41M	-$28.98M
Capital Expenditure	-$6.13M	-$2.37M	-$6.17M	-$4.35M	-$6.45M	-$10.11M
Free Cash Flow	$4.05M	$8.05M	$9.60M	-$7.44M	-$38.86M	-$39.09M
Depreciation & Amortisation	$5.68M	$6.19M	$6.47M	$6.88M	$6.81M	$6.71M
Stock-Based Compensation	$3.98M	$7.81M	$10.59M	$9.78M	$9.00M	$6.34M
Investing Cash Flow	-$9.41M	-$36.35M	-$4.69M	-$11.07M	-$17.25M	-$5.63M
Financing Cash Flow	$13.72M	$346.00K	$10.77M	$23.19M	$38.59M	$1.00M
Net Change in Cash	$14.49M	-$25.58M	$21.85M	$9.03M	-$11.07M	-$33.61M

Market Snapshot

About

GeneDx Holdings Corp. is a leading genomic testing and diagnostic company that provides comprehensive genetic testing services. The company specializes in whole exome and whole genome sequencing, offering solutions for rare disease diagnosis, cancer genomics, and reproductive health.